Medication Development Program, NIDA IRP, Baltimore, Maryland 21224, United States.
Medicinal Chemistry Section, NIDA IRP, Baltimore, Maryland 21224, United States.
ACS Chem Neurosci. 2023 Aug 2;14(15):2802-2810. doi: 10.1021/acschemneuro.3c00354. Epub 2023 Jul 19.
Understanding the neurochemistry underlying sex differences in psychostimulant use disorders (PSUD) is essential for developing related therapeutics. Many psychostimulants, like cocaine, inhibit the dopamine transporter (DAT), which is largely thought to account for actions related to their misuse and dependence. Cocaine-like, typical DAT inhibitors preferentially bind DAT in an outward-facing conformation, while atypical DAT inhibitors, like modafinil, prefer a more inward-facing DAT conformation. Modafinil and -modafinil have emerged as potential therapeutic options for selected populations of individuals affected by PSUD. In addition, analogs of modafinil (JJC8-088 and JJC8-091) with different pharmacological profiles have been explored as potential PSUD medications in preclinical models. In this work, we employ fast scan cyclic voltammetry (FSCV) to probe nucleus accumbens shell (NAS) dopamine (DA) dynamics in C57BL/6 male and female mice. We find that cocaine slowed DA clearance in both male and female mice but produced more robust increases in evoked NAS DA in female mice. -Modafinil produced mild increases in evoked NAS DA and slowed DA clearance across the sexes. The modafinil analog JJC8-088, a typical DAT inhibitor, produced increases in evoked NAS DA in female and male mice. Finally, JJC8-091, an atypical DAT inhibitor, produced limited increases in evoked NAS DA and slowed DA clearance in both sexes. In this work we begin to tease out how sex differences may alter the effects of DAT targeting and highlight how this may help focus research toward effective treatment options for PSUD.
了解精神兴奋剂使用障碍(PSUD)中性别差异的神经化学基础对于开发相关疗法至关重要。许多精神兴奋剂,如可卡因,会抑制多巴胺转运体(DAT),这在很大程度上解释了它们与滥用和依赖相关的作用。可卡因样、典型的 DAT 抑制剂优先结合向外开放构象的 DAT,而非典型的 DAT 抑制剂,如莫达非尼,则优先结合更向内开放构象的 DAT。莫达非尼和它的代谢产物阿莫达非尼已经成为治疗 PSUD 特定人群的潜在选择。此外,不同药理学特征的莫达非尼类似物(JJC8-088 和 JJC8-091)已被探索作为潜在的 PSUD 药物在临床前模型中。在这项工作中,我们使用快速扫描循环伏安法(FSCV)来探测 C57BL/6 雄性和雌性小鼠伏隔核壳(NAS)多巴胺(DA)的动力学。我们发现可卡因在雄性和雌性小鼠中都能减缓 DA 的清除,但在雌性小鼠中引起的 NAS DA 诱发增加更为明显。阿莫达非尼产生轻度的 NAS DA 诱发增加,并减缓了跨性别 DA 的清除。莫达非尼类似物 JJC8-088,一种典型的 DAT 抑制剂,在雌性和雄性小鼠中都能增加 NAS DA 的诱发。最后,非典型的 DAT 抑制剂 JJC8-091,在两性中仅引起有限的 NAS DA 诱发增加,并减缓 DA 清除。在这项工作中,我们开始梳理性别差异如何改变 DAT 靶向的作用,并强调这如何有助于将研究重点集中在有效的 PSUD 治疗选择上。